Helen Albert

Pandemics remain unusual occurrences, but research suggests that factors such as climate change may be increasing the risk in the future.

New antibiotic mechanism sees molecule infiltrate bacterial cells and destroy them from the inside

US big pharma Gilead Sciences has won an accelerated US FDA approval for peroxisome proliferator-activated receptor delta agonist seladelpar (Livdelzi) for

The California-based biotech announced this week it had achieved good results in a phase 3 trial of its lead candidate izokibep, a small protein

The US regulator has confirmed a delay to the approval of linvoseltamab while a manufacturing issue is resolved with a third-party provider.

The US regulator has confirmed a delay to the approval of linvoseltamab while a manufacturing issue is resolved with a third-party provider.

Results from a phase 2 trial of the candidate schizophrenia drug, currently known as NBI-1117568, show that it met the primary trial endpoint of a

Researchers based at the University of California (UC) San Diego have produced a wearable device that can be wrapped around a finger like a plaster

A study led by Massachusetts General Hospital (MGH) shows women with hepatocellular carcinoma are less likely to receive a liver transplant than men with the same condition.

The Swiss biotech, which is still at the seed stage of funding, could receive more than US $1 billion in combined payments from the US big pharma if co-developed products reach the clinic.